High-throughput asparaginase activity assay in serum of children with leukemia

International Journal of Clinical and Experimental Medicine

Volumn 6, Issue 7, 2013, Pages 478-487

  Fernandez, Christian A ^a   Cai, Xiangjun ^a   Elozory, Allie ^a   Liu, Chengcheng ^a   Panetta, J Carl ^a   Jeha, Sima ^a   Molinelli, Alejandro R ^a   Relling, Mary V ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Acute lymphoblastic leukemia; Asparaginase; Asparaginase activity; Clinical assay; High throughput

Indexed keywords

ASPARAGINASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; SERUM ALBUMIN;

ACCURACY; ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CALIBRATION; CHILD; CONTROLLED STUDY; DILUTION; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG EFFICACY; DRUG EXPOSURE; DRUG MONITORING; DRUG STABILITY; ENZYME MECHANISM; HUMAN;

EID: 84881077526     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Asselin BL, Whitin JC, Coppola DJ, Rupp IP, Sallan SE and Cohen HJ. Comparative pharmacokinetic studies of three asparaginase preparations. J Clin Oncol 1993; 11: 1780-1786.
2. Lanvers C, Vieira Pinheiro JP, Hempel G, Wuerthwein G and Boos J. Analytical validation of a microplate reader-based method for the therapeutic drug monitoring of L-asparaginase in human serum. Anal Biochem 2002; 309: 117-126.
3. Panetta JC, Gajjar A, Hijiya N, Hak LJ, Cheng C, Liu W, Pui CH and Relling MV. Comparison of native E. coli and PEG asparaginase pharmacokinetics and pharmacodynamics in pediatric acute lymphoblastic leukemia. Clin Pharmacol Ther 2009; 86: 651-658.
4. Pieters R, Appel I, Kuehnel HJ, Tetzlaff-Fohr I, Pichlmeier U, van der Vaart I, Visser E and Stigter R. Pharmacokinetics, pharmacodynamics, efficacy, and safety of a new recombinant asparaginase preparation in children with previously untreated acute lymphoblastic leukemia: a randomized phase 2 clinical trial. Blood 2008; 112: 4832-4838.
5. Dinndorf PA, Gootenberg J, Cohen MH, Keegan P and Pazdur R. FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL). Oncologist 2007; 12: 991-998.
6. Raetz EA and Salzer WL. Tolerability and efficacy of L-asparaginase therapy in pediatric patients with acute lymphoblastic leukemia. J Pediatr Hematol Oncol 2010; 32: 554-563.
7. Rizzari C, Zucchetti M, Conter V, Diomede L, Bruno A, Gavazzi L, Paganini M, Sparano P, Lo NL, Arico M, Milani M and D'Incalci M. L-asparagine depletion and L-asparaginase activity in children with acute lymphoblastic leukemia receiving i.m. or i.v. Erwinia C. or E. coli L-asparaginase as first exposure. Ann Oncol 2000; 11: 189-93.
8. Panosyan EH, Seibel NL, Martin-Aragon S, Gaynon PS, Avramis IA, Sather H, Franklin J, Nachman J, Ettinger LJ, La M, Steinherz P, Cohen LJ, Siegel SE and Avramis VI. Asparaginase antibody and asparaginase activity in children with higher-risk acute lymphoblastic leukemia: Children's Cancer Group Study CCG1961. J Pediatr Hematol Oncol 2004; 26: 217-226.
9. Muller HJ and Boos J. Use of L-asparaginase in childhood ALL. Crit Rev Oncol Hematol 1998; 28: 97-113.
10. Oettgen HF, Stephenson PA, Schwartz MK, Leeper RD, Tallai L, Tan CC, Clarkson BD, Golbey RB, Krakoff IH, Karnofsky DA, Murphy ML and Burchenal JH. Toxicity of E. coli L-asparaginase in man. Cancer 1970; 25: 253-278.
11. Avramis VI, Avramis EV, Hunter W and Long MC. Immunogenicity of native or pegylated E. coli and Erwinia asparaginases assessed by ELISA and surface plasmon resonance (SPRbiacore) assays of IgG antibodies (Ab) in sera from patients with acute lymphoblastic leukemia (ALL). Anticancer Res 2009; 29: 299-302.
12. Ebeid EN, Kamel MM and Ali BA. Detection of anti-asparaginase antibodies during therapy with E. coli asparaginase in children with newly diagnosed acute lymphoblastic leukemia and lymphoma. J Egypt Natl Canc Inst 2008; 20: 127-133.
13. Vrooman LM, Supko JG, Neuberg DS, Asselin BL, Athale UH, Clavell L, Kelly KM, Laverdiere C, Michon B, Schorin M, Cohen HJ, Sallan SE and Silverman LB. Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia. Pediatr Blood Cancer 2010; 54: 199-205.
14. Avramis VI, Sencer S, Periclou AP, Sather H, Bostrom BC, Cohen LJ, Ettinger AG, Ettinger LJ, Franklin J, Gaynon PS, Hilden JM, Lange B, Majlessipour F, Mathew P, Needle M, Neglia J, Reaman G, Holcenberg JS and Stork L. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study. Blood 2002; 99: 1986-1994.
15. Ylikangas P and Mononen I. A fluorometric assay for L-asparaginase activity and monitoring of L-asparaginase therapy. Anal Biochem 2000; 280: 42-45.
16. Tagami S and Matsuda K. An enzymatic method for the kinetic measurement of L-asparaginase activity and L-asparagine with an ammonia gas-sensing electrode. Chem Pharm Bull (Tokyo) 1990; 38: 153-155.
17. Nath CE, Dallapozza L, Eslick AE, Misra A, Carr D and Earl JW. An isocratic fluorescence HPLC assay for the monitoring of l-asparaginase activity and l-asparagine depletion in children receiving E. colil-asparaginase for the treatment of acute lymphoblastic leukaemia. Biomed Chromatogr 2009; 23: 152-159.
18. Avramis VI, Martin-Aragon S, Avramis EV and Asselin BL. Pharmacoanalytical assays of Erwinia asparaginase (erwinase) and pharmacokinetic results in high-risk acute lymphoblastic leukemia (HR ALL) patients: simulations of erwinase population PK-PD models. Anticancer Res 2007; 27: 2561-2572.
19. Kojima Y and Wacker WE. An enzymatic method for the measurement of asparagine and a new assay of asparaginase activity. J Lab Clin Med 1969; 74: 521-526.
20. Pui CH, Campana D, Pei D, Bowman WP, Sandlund JT, Kaste SC, Ribeiro RC, Rubnitz JE, Raimondi SC, Onciu M, Coustan-Smith E, Kun LE, Jeha S, Cheng C, Howard SC, Simmons V, Bayles A, Metzger ML, Boyett JM, Leung W, Handgretinger R, Downing JR, Evans WE and Relling MV. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med 2009; 360: 2730-2741.
21. Pui CH CD, Sandlund JT, Bhojwani D, Evans WE, Relling MV, Jeha S. Treatment of childhood acute lymphoblastic leukemia without cranial irradiation. Ann Hematol 2011; 90: 61-63.
22. Muller HJ, Beier R, da Palma JC, Lanvers C, Ahlke E, von Schutz V, Gunkel M, Horn A, Schrappe M, Henze G, Kranz K and Boos J. PEG-asparaginase (Oncaspar) 2500 U/m(2) BSA in reinduction and relapse treatment in the ALL/NHL-BFM protocols. Cancer Chemother Pharmacol 2002; 49: 149-154.
23. Beal S, Sheiner L and Boeckmann A. NONMEM user's guides. Ellicott City, MD, USA: Icon Development Solutions, 1989-2011.
24. van den Berg H. Asparaginase revisited. Leuk Lymphoma 2011; 52: 168-178.
25. Rizzari C, Conter V, Stary J, Colombini A, Moericke A and Schrappe M. Optimizing asparaginase therapy for acute lymphoblastic leukemia. Curr Opin Oncol 2013; 25 Suppl 1: 1-9.
26. Zalewska-Szewczyk B, Andrzejewski W, Mlynarski W, Jedrychowska-Danska K, Witas H and Bodalski J. The anti-asparagines antibodies correlate with L-asparagines activity and may affect clinical outcome of childhood acute lym phoblastic leukemia. Leuk Lymphoma 2007; 48: 931-936.
27. Liu C, Kawedia JD, Cheng C, Pei D, Fernandez CA, Cai X, Crews KR, Kaste SC, Panetta JC, Bowman WP, Jeha S, Sandlund JT, Evans WE, Pui CH and Relling MV. Clinical utility and implications of asparaginase antibodies in acute lymphoblastic leukemia. Leukemia 2012; 26: 2303-2309.
28. Woo MH, Hak LJ, Storm MC, Evans WE, Sandlund JT, Rivera GK, Wang B, Pui CH and Relling MV. Anti-asparaginase antibodies following E. coli asparaginase therapy in pediatric acute lymphoblastic leukemia. Leukemia 1998; 12: 1527-1533.
29. Woo MH, Hak LJ, Storm MC, Sandlund JT, Ribeiro RC, Rivera GK, Rubnitz JE, Harrison PL, Wang B, Evans WE, Pui CH and Relling MV. Hypersensitivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leuke-mia. J Clin Oncol 2000; 18: 1525-1532.
30. Peterson RG, Handschumacher RE and Mitchell MS. Immunological responses to L-asparaginase. J Clin Invest 1971; 50: 1080-1090.
31. Strullu M, Corradini N, Audrain M, Orsonneau JL, Bouige D, Thomare P, Vermot-Desroches C, Mansuy A, Legrand A, Roze JC, Mohty M and Mechinaud F. Silent hypersensitivity to Escherichia coli asparaginase in children with acute lymphoblastic leukemia. Leuk Lymphoma 2010; 51: 1464-1472.